Nomura Stock Upgraded to Buy by BofA as Stronger ROE and Earnings Growth Boost Outlook 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
China Eastern Orders 25 Airbus A330neo Jets in $9.35 Billion Deal to Boost International Expansion 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
SpaceX, Charter Communications Explore Mobile Partnership to Expand Starlink Wireless Service 
Italy Investigates Microsoft Over Microsoft 365 AI Subscription Price Hike 
VANCOUVER, British Columbia and CAMBRIDGE, Mass., March 01, 2017 -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that the company will participate in the Cowen and Company 37th Annual Health Care Conference in Boston. Chief Executive Officer Mary Szela is scheduled to present on Wednesday, March 8, 2017 at 8:40 a.m. EST.
The presentation will be webcast live and may be accessed for up to 90 days following the conference by visiting the “Investors” section of Novelion’s website, www.novelion.com.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.
CONTACT: Amanda Murphy, Director, Investor Relations & Corporate Communications Novelion Therapeutics 857-242-5024 [email protected]
